Clinical trials: Chronic Disease Management
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Immune Thrombocytopenic Purpura
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
- Trial name
- FIT (NCT02076412)
- Testing
- Fostamatinib Disodium
- Where
- 35 sites in United States, Austria and 7 more
- Volunteers
- 74 people
- Sponsor
- Rigel Pharmaceuticals
Chronic Myeloid Leukemia (CML)
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
This is an open label, non randomized, prospective, multicenter, phase II clinical trial evaluating nilotinib 400 mg BID for the treatment of newly diagnosed CML-AP patients.
- Trial name
- MACS1881 (NCT01605981)
- Testing
- AMN107
- Where
- 18 sites in Brazil
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)
This is a response-driven study of tildrakuzumab for the treatment of moderate to severe chronic plaque psoriasis. The primary study hypothesis is that one or more doses of tildrakizumab will be superior to placebo for the…
- Trial name
- NCT01225731
- Testing
- tildrakizumab
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C
It is a multi-center study of the efficacy of a new Pegylated Hansenula-derived recombinant interferon α 2a (Reiferon Retard® 160 µg once weekly in combination with ribavirin in treatment of Egyptian patients with chronic…
- Trial name
- HAPIC (NCT01649245)
- Testing
- Reiferon retard
- Where
- Egypt
- Volunteers
- 5,000 people
- Sponsor
- MinaPharm Pharmaceuticals
Venous Insufficiency
Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)
It is hoped that with the use of medication, occurs improvement of the CVI parameters, such as edema, pain, night cramps, functional discomfort, heavy feeling and that the drug test is non-inferior than the comparator.
- Trial name
- NCT01110512
- Testing
- Flavonid, Daflon
- Where
- Brazil
- Volunteers
- 140 people
- Sponsor
- Azidus Brasil
Hepatitis C, Chronic
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
This is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus (HCV) who have a viral response at the end of treatment with pegylated…
- Trial name
- FAST-4 (NCT00723645)
- Volunteers
- 279 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Cystic Fibrosis Bronchiectasis
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic…
- Trial name
- NCT01515007
- Testing
- Ciprofloxacin dispersion for inhalation
- Where
- 109 sites in United States, Australia and 14 more
- Volunteers
- 278 people
- Sponsor
- Aradigm Corporation
Excessive Daytime Sleepiness, Narcolepsy
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea…
- Conditions
- Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
- Trial name
- NCT00228553
- Testing
- Armodafinil 100 to 250 mg/day
- Where
- 100 sites in United States, Australia and 5 more
- Volunteers
- 743 people
- Sponsor
- Cephalon
Chronic Kidney Disease
A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
The study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.
- Trial name
- NCT07419828
- Testing
- HRS-1780 tablets
- Where
- China
- Volunteers
- 5,386 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
The timing of initiating short-term treatment for COPD exacerbations with oral corticosteroids and/or antibiotic therapy has been shown to influence the recovery time of exacerbations with early initiation of exacerbation therapy…
- Trial name
- NCT01431911
- Testing
- Early maintenance treatment, Delayed Maintenance treatment
- Volunteers
- 3,806 people
- Sponsor
- GlaxoSmithKline
Anemia
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis, with treatment up to 52 weeks.
- Trial name
- NCT02652819
- Testing
- FG-4592
- Where
- 30 sites in China
- Volunteers
- 154 people
- Sponsor
- Kyntra Bio
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01040130
- Testing
- Olodaterol (BI 1744)
- Where
- 19 sites in Australia, Austria and 3 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Exacerbations Among Patients Receiving Breztri (EROS Study)
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Retrospective Studies
- Trial name
- NCT06514144
- Testing
- BGF
- Where
- United States
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Psoriasis Vulgaris
Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis
The main objective of this study is to establish the efficacy and safety of Psorax35 supplementation in patients with mild to moderate Psoriasis.
- Trial name
- NCT03359577
- Testing
- Psorax35, MCT oil
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Arctic Nutrition AS
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Heart Failure
QuickOpt Chronic Study
The purpose of this study is to demonstrate that QuickOpt optimization can be as an alternative method for CRTP/D patients' optimization in clinical practice through the comparison of the improvement differences between the…
- Trial name
- NCT01172067
- Testing
- Cardiac Resynchronization Therapy, Optimization using echocardiography
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Chronic Myeloid Leukemia
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
- Trial name
- NCT01394666
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia…
- Trial name
- NCT01274351
- Testing
- Nilotinib
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.